ストックスクリーナーアプリを入手
41.50
0.95%
0.39
Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース
Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR - GlobeNewswire Inc.
Corcept Looks To End Teva's Mifepristone Antitrust Case - Law360
Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook - EIN News
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire Inc.
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeat
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Teva Wins FDA Approval For Schizophrenia Innovation - Healthcare Digital
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Pretax income of Teva Pharmaceutical Industries Limited – BMV:TEVA1/N - TradingView
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo Finance
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Earnings Transcripts - GuruFocus
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Price, Trades & News - GuruFocus
Teva Pharmaceutical Industries Ltd. Advanced Charts | TEVA - Barron's
Teva Pharmaceutical Industries Ltd. Financials | TEVA - Barron's
Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza - Haaretz
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo! Finance Canada
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth InitiativesSlideshow (NYSE:TEVA) 2026-10-09 - Seeking Alpha
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Oppenheimer Adjusts Teva Pharmaceutical Industries PT to $52 From $50, Maintains Outperform Rating - Yahoo Finance
Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives - Fierce Pharma
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Teva Pharmaceutical Industries Ltd. Research & Ratings | TEVA1N - Barron's
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia - Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. Company & People | TEVA - Barron's
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price - Simply Wall Street
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround - The Motley Fool
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Short Interest Update - MarketBeat
Is Teva Pharmaceutical Industries (TEVA) Undervalued Following New Phase 3 Schizophrenia Data? - simplywall.st
Teva, Wyeth Show How Claimed Advances Shape Enablement - Law360
Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026 - quiverquant.com
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire Inc.
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire Inc.
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock - Moomoo
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - finance.yahoo.com
Oppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - Yahoo Finance
TEVA: Investment grade status enables accelerated innovation, robust launches, and renewed generics growth - TradingView
TEVA: Focus shifts to innovation, high-margin launches, and renewed growth in generics and biosimilars - TradingView
Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock - MarketBeat
1.91%
1.55%
大文字化:
|
ボリューム (24 時間):